Outcomes after resection of cholangiocellular carcinoma

被引:30
作者
Huang, JL [1 ]
Biehl, TR [1 ]
Lee, FT [1 ]
Zimmer, PW [1 ]
Ryan, JA [1 ]
机构
[1] Virginia Mason Med Ctr, Dept Gen Thorac & Vasc Surg, Seattle, WA 98111 USA
关键词
cholangiocellular carcinoma; liver mass; hepatic resection; intrahepatic cholangiocarcinoma;
D O I
10.1016/j.amjsurg.2004.01.007
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Cholangiocellular carcinoma (CCC) is a rare primary liver malignancy that arises from intrahepatic bile duct canaliculi and presents as a liver mass. Our purpose is to report operative morbidity and mortality and to determine long-term survival after resection for CCC. Methods: Retrospective review of 31 consecutive patients who underwent resection during a 20-year period. Results: Thirty-day hospital mortality was 3%, and postoperative morbidity was 38%. Kaplan-Meier 5-year survival was 35%; mean survival was 37 months; absolute 5-year survival was 33%. Mean survival in stages I, II, IIIA, and IIIC were 57, 33, 26, and 14 months, respectively (P = 0.03 comparing I to >I). Recurrence occurred in 18 patients; 89% were in the liver. Carbohydrate antigen 19-9 >100 U/mL was found to be an indicator of poor prognosis (P = 0.009). Conclusions: Resection for CCC can be performed with acceptable morbidity and mortality rates and results in good survival and cure. Hepatic recurrence is common. Carbohydrate antigen 19-9 may be useful in determining prognosis. (C) 2004 Excerpta Medica, Inc. All rights reserved.
引用
收藏
页码:612 / 617
页数:6
相关论文
共 20 条
[1]   Hepatic resection and transplantation for peripheral cholangiocarcinoma [J].
Casavilla, FA ;
Marsh, JW ;
Iwatsuki, S ;
Todo, S ;
Lee, RG ;
Madariaga, JR ;
Pinna, A ;
Dvorchik, I ;
Fung, JJ ;
Starzl, TE .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1997, 185 (05) :429-436
[2]   Peripheral cholangiocarcinoma (cholangiocellular carcinoma): Clinical features, diagnosis and treatment [J].
Chen, MF .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (12) :1144-1149
[3]  
Chu K M, 1999, J Hepatobiliary Pancreat Surg, V6, P149, DOI 10.1007/s005340050098
[4]  
El Rassi Z, 1999, EUR J SURG ONCOL, V25, P375
[5]  
Greene FL., 2002, AJCC CANC STAGING HD, V6th
[6]  
Kim H J, 1999, J Hepatobiliary Pancreat Surg, V6, P142, DOI 10.1007/s005340050097
[7]  
Lieser M J, 1998, J Hepatobiliary Pancreat Surg, V5, P41, DOI 10.1007/PL00009949
[8]   Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology [J].
Okuda, K ;
Nakanuma, Y ;
Miyazaki, M .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (10) :1049-1055
[9]   Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States [J].
Patel, T .
HEPATOLOGY, 2001, 33 (06) :1353-1357
[10]   Aggressive surgical treatment of intrahepatic cholangiocarcinoma: Predictors of outcomes [J].
Roayaie, S ;
Guarrera, JV ;
Ye, MQ ;
Thung, SN ;
Emre, S ;
Fishbein, TM ;
Guy, SR ;
Sheiner, PA ;
Miller, CM ;
Schwartz, ME .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (04) :365-372